Home
Resources
Publications
PAD4: Pathophysiology, Current Therapeutics and Future Perspective in Rheumatoid Arthritis

PAD4: Pathophysiology, Current Therapeutics and Future Perspective in Rheumatoid Arthritis

Sindhu Koushik, Nivedita Joshi, Shruthi Nagaraju, Sameer Mahmood, Krishna Mudeenahally, Ramya Padmavathy, Sooriya Kumar Jegatheesan, Ramesh Mullangi, Sriram Rajagopal

Expert Opin Ther Targets. 2017 Apr;21(4):433-447.

PMID: 28281906

Abstract:

Peptidyl arginine deiminase 4 (PAD4) is an enzyme that plays an important role in gene expression, turning out genetic code into functional products in the body. It is involved in a key post translational modification, which involves the conversion of arginine to citrulline. It regulates various processes such as apoptosis, innate immunity and pluripotency, while its dysregulation has a great impact on the genesis of various diseases. Over the last few years PAD4 has emerged as a potential therapeutic target for the treatment of rheumatoid arthritis (RA). Areas covered: In this review, we discuss the basic structure and function of PAD4, along with the role of altered PAD4 activity in the onset of RA and other maladies. We also elucidate the role of PAD4 variants in etiology of RA among several ethnic groups and the current pre-clinical inhibitors to regulate PAD4. Expert opinion: Citrullination has a crucial role in RA and several other disorders. Since PAD4 is an initiator of the citrullination, it is an important therapeutic target for inflammatory diseases. Therefore, an in depth knowledge of the roles and activity of PAD4 is required to explore more effective ways to conquer PAD4 related ailments, especially RA.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP1652591815	GSK484		1652591-81-5	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: